News

Researchers tested blood samples from cystic fibrosis (CF) patients and identified distinct gene expression patterns that could lead to patient-tailored treatments, a study reports. The study, “Identification of molecular signatures of cystic fibrosis disease status using plasma-based functional genomics,” was published in Physiological Genomics. To better understand…

Vast Therapeutics announced that it received funding from the Cystic Fibrosis Foundation (CFF) to support further development of BIOC51, the company’s investigative treatment for antibiotic-resistant bacteria, including Pseudomonas aeruginosa, that is often the cause of lung infections in cystic fibrosis (CF) patients. P. aeruginosa infections set in when mucus accumulation…

Purdue University researchers have invented a new way of delivering two antibiotics (colistin and ciprofloxacin) deep into the lungs of cystic fibrosis (CF) patients, enabling much more effective killing of antibiotic-resistant bacteria without exposing patients to high systemic doses of these therapies. “We are providing a promising option to fight…

Health Canada has approved Orkambi (ivacaftor/lumacaftor) to treat preschoolers with cystic fibrosis (CF) who carry the F508del mutation in both gene copies of the CFTR gene. Orkambi, developed by Vertex Pharmaceuticals, in the first disease-modifying therapy in Canada for children ages 2 to 5 with CF. It previously was …

Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial potential of its investigational candidate, AR-501 (gallium citrate), against chronic lung infections in patients with cystic fibrosis (CF). The study (NCT03669614) is expected to enroll approximately 48 healthy adult volunteers and…

The effects of CFTR modulator therapies such as Kalydeco (ivacaftor) can be more reliably assessed using a test that specifically measures the sweating dependent on CFTR, called C-sweat rate, than using classic sweat tests or lung function measurements, a study reports. This kind of test was sensitive enough to reveal that…

Wrist-worn monitoring devices are an acceptable method of objectively tracking the levels of physical activity of children and young people with cystic fibrosis (CF), a study reports. The study, “A Formative Study Exploring Perceptions of Physical Activity and Physical Activity Monitoring Among Children and Young People with Cystic Fibrosis…

A recent study confirmed the presence of increased serum levels of interleukin-7 (IL-7) in cystic fibrosis (CF) patients, compared with healthy controls. The researchers could establish a link between higher IL-7 levels and worse lung function in patients, suggesting a possible biomarker for CF. The study, “Higher…

Air Next, a small, simple-to-use handheld spirometer, could transform cystic fibrosis (CF) treatment, allowing patients to monitor their own lung function at home and share the results remotely with their healthcare team. Air Next connects via Bluetooth to a user-friendly smartphone app called Aria. Both Air Next spirometer and the Aria…

Aridis Pharmaceuticals is planning to launch a Phase 1/2a clinical trial in the beginning of 2019 to evaluate the potential of its investigational antibacterial compound AR-501 (gallium citrate) in patients with cystic fibrosis (CF). This follows the approval of the Investigational New Drug application for AR-501 by…